Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Aarhus |
---|---|
Information provided by: | University of Aarhus |
ClinicalTrials.gov Identifier: | NCT00619034 |
The purpose of this study is to determine if diabetic retinopathy can be treated with prostaglandin analogues, prostaglandin synthesis inhibitors or carbonic anhydrases inhibitors.
Condition | Intervention |
---|---|
Diabetic Retinopathy |
Drug: Latanoprost, diclofenac and dorzolamide (eyedrops) |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Investigator), Active Control, Crossover Assignment, Efficacy Study |
Official Title: | Pharmacological Intervention Against Diabetic Retinal Flow Disturbances. |
Estimated Enrollment: | 80 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Latanoprost, diclofenac and dorzolamide (eyedrops)
1 eyedrop twice daily in one week
|
Disturbances in retinal perfusion is believed to be involved in the pathophysiology of diabetic retinopathy. These disturbances may be due to changes in the basal diameter of retinal arterioles and to disturbances in the autoregulation of the diameter of these vessels when the blood pressure and the retinal metabolism changes. In vitro studies have shown that prostaglandins and carbonic anhydrases inhibitors are involved in the tone regulation of retinal arterioles, but it is unknown whether this finding is relevant in clinical practice. This can be tested in vivo by an retinal vessel analyzer measuring the dynamics of the retinal vessel diameter changes.
Ages Eligible for Study: | 20 Years to 30 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Kathrine B Tilma, MD | +4589493250 | katht@as.aaa.dk |
Denmark | |
Department of Ophthalmology | Recruiting |
Aarhus, Denmark, 8000 | |
Contact: Kathrine B Tilma, MD +45 89493250 katht@as.aaa.dk | |
Principal Investigator: Kathrine B Tilma, MD |
Principal Investigator: | Kathrine B Tilma, MD | Department of Ophthalmology - Aarhus, Denmark |
Responsible Party: | Department of Ophthalmology ( Øjenafd. J ) |
Study ID Numbers: | 2007-001697-84, XAVOT |
Study First Received: | February 7, 2008 |
Last Updated: | September 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00619034 |
Health Authority: | Denmark: Danish Medicines Agency |
Eye Diseases Vascular Diseases Diabetes Mellitus Endocrine System Diseases Diclofenac Tetrahydrozoline Latanoprost |
Diabetic Angiopathies Diabetic Retinopathy Endocrinopathy Retinal Diseases Diabetes Complications Dorzolamide |
Carbonic Anhydrase Inhibitors Molecular Mechanisms of Pharmacological Action Therapeutic Uses Enzyme Inhibitors |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |